Data previously presented at the 2004 American College of Rheumatology Annual Meeting, San Antonio, Texas, and 2005 American Geriatrics Society Annual Meeting, Orlando, Florida.
Safety and Efficacy of Teriparatide in Elderly Women with Established Osteoporosis: Bone Anabolic Therapy from a Geriatric Perspective
Version of Record online: 30 MAR 2006
Journal of the American Geriatrics Society
Volume 54, Issue 5, pages 782–789, May 2006
How to Cite
Boonen, S., Marin, F., Mellstrom, D., Xie, L., Desaiah, D., Krege, J. H. and Rosen, C. J. (2006), Safety and Efficacy of Teriparatide in Elderly Women with Established Osteoporosis: Bone Anabolic Therapy from a Geriatric Perspective. Journal of the American Geriatrics Society, 54: 782–789. doi: 10.1111/j.1532-5415.2006.00695.x
- Issue online: 2 MAY 2006
- Version of Record online: 30 MAR 2006
- geriatric patients;
OBJECTIVES: To assess the safety and efficacy of teriparatide in patients aged 75 and older and compare these findings with those of women younger than 75 using data from the Fracture Prevention Trial (FPT).
DESIGN: The FPT was a randomized, multicenter, double-blind, placebo-controlled study.
SETTING: The FPT multicenter international study.
PARTICIPANTS: Postmenopausal women aged 42 to 86 were randomized to placebo (N=544) or teriparatide 20 μg (N=541) by daily self-injection for a median of 19 months. Patients received daily oral supplements of 1,000 mg calcium and 400 to 1,200 IU vitamin D. For this analysis, subgroups were defined according to patient age younger than 75 (N=841) and 75 and older (N=244).
MEASUREMENTS: The effects of teriparatide on bone mineral density (BMD) of the lumbar spine and femoral neck; the incidence of new vertebral and new nonvertebral fragility fractures; bone turnover markers, including bone-specific alkaline phosphatase; and urinary deoxypyridinoline corrected for creatinine clearance, as well as the safety of teriparatide, were investigated.
RESULTS: There were no significant treatment-by-age interactions for the bone turnover markers, femoral neck BMD, vertebral fractures, nonvertebral fragility fractures, height loss, hyperuricemia, or hypercalcemia. A significant treatment-by-age interaction for lumbar spine BMD (P=.08) was due to an increase in BMD observed in the placebo group aged 75 and older. There were no treatment-by-age interactions for important treatment-emergent adverse events (TEAEs), including back pain, nausea, leg cramps, and dizziness. The most important TEAEs in women aged 80 and older (23 patients from the placebo group and 25 patients from the teriparatide group) were also reviewed; no unexpected TEAEs were found in the patients treated with teriparatide. These results indicate that the clinical effects of teriparatide were consistent in the older and younger women.
CONCLUSION: Age does not affect the safety and efficacy of teriparatide in postmenopausal women with osteoporosis.